| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 300049 from our risk checks.
Inner Mongolia Furui Medical Science Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥49.73 |
| 52 Week High | CN¥57.50 |
| 52 Week Low | CN¥20.34 |
| Beta | -0.25 |
| 1 Month Change | 0.081% |
| 3 Month Change | 32.93% |
| 1 Year Change | 68.58% |
| 3 Year Change | 492.02% |
| 5 Year Change | 418.02% |
| Change since IPO | 390.19% |
Recent News & Updates
Shareholder Returns
| 300049 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 8.8% | 0.8% | -0.4% |
| 1Y | 68.6% | -13.4% | -14.4% |
Return vs Industry: 300049 exceeded the CN Pharmaceuticals industry which returned -13.4% over the past year.
Return vs Market: 300049 exceeded the CN Market which returned -14.4% over the past year.
Price Volatility
| 300049 volatility | |
|---|---|
| 300049 Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 300049's share price has been volatile over the past 3 months.
Volatility Over Time: 300049's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 742 | Xin Lin | www.fu-rui.com |
Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. It operates in two segments, pharmaceutical production and sales; and diagnostic equipment R&D, production and sales.
Inner Mongolia Furui Medical Science Co., Ltd. Fundamentals Summary
| 300049 fundamental statistics | |
|---|---|
| Market cap | CN¥13.08b |
| Earnings (TTM) | CN¥102.58m |
| Revenue (TTM) | CN¥1.15b |
127.5x
P/E Ratio11.3x
P/S RatioIs 300049 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300049 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.15b |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥1.15b |
| Other Expenses | CN¥1.05b |
| Earnings | CN¥102.58m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | 0.39 |
| Gross Margin | 100.00% |
| Net Profit Margin | 8.90% |
| Debt/Equity Ratio | 2.4% |
How did 300049 perform over the long term?
See historical performance and comparison